---
title: "PYXS: MICVO showed durable responses in phase 1, supporting a planned global Phase 3 trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306107284.md"
description: "In 33 patients with 2L+ recurrent/metastatic HNSCC, MICVO showed a 39% confirmed ORR, 6.7-month median PFS and 9.2-month median response duration. Results support a global Phase 3 trial planned for mid-2027.Original document: Pyxis Oncology, Inc. [PYXS] Press release — Nov. 19 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-11-19T11:04:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306107284.md)
  - [en](https://longbridge.com/en/news/306107284.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306107284.md)
generator: "portal-rs"
---

# PYXS: MICVO showed durable responses in phase 1, supporting a planned global Phase 3 trial

In 33 patients with 2L+ recurrent/metastatic HNSCC, MICVO showed a 39% confirmed ORR, 6.7-month median PFS and 9.2-month median response duration. Results support a global Phase 3 trial planned for mid-2027.

Original document: Pyxis Oncology, Inc. \[PYXS\] Press release — Nov. 19 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [PYXS.US](https://longbridge.com/en/quote/PYXS.US.md)

## Related News & Research

- [Guggenheim Remains a Buy on Pyxis Oncology (PYXS)](https://longbridge.com/en/news/306281515.md)
- [William Blair upgrades Pyxis Oncology to Outperform from Market Perform](https://longbridge.com/en/news/306274949.md)
- [AI solves 167-year-old maths problem, Anthropic researcher claims](https://longbridge.com/en/news/306318851.md)
- [Anthropic lacks ‘basic moral compass’, say publishers](https://longbridge.com/en/news/306295252.md)
- [Marvell Stock’s (MRVL) Plunge Is My Opportunity to Buy](https://longbridge.com/en/news/306273400.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**